Biological
TBI-1401(HF10)
TBI-1401(HF10) is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed267%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_2
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
NCT03153085
active_not_recruitingphase_1
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
NCT03252808
completedphase_1
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
NCT02428036
Clinical Trials (3)
Showing 3 of 3 trials
NCT03153085Phase 2
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
NCT03252808Phase 1
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
NCT02428036Phase 1
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3